The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Open accessAbstract
BACKGROUND: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and beta-amyloid 42 (Abeta42) peptide in patients with AD have been well documented, but the relationship between these biomarkers and neuropathologic changes in the brain is not established. OBJECTIVE: To study the relationship between antemortem CSF biomarker levels and Alzheimer-type neuropathologic changes in the brain. DESIGN: Cross-sectional study to correlate levels of CSF Abeta42, total tau, and phosphorylated tau protein with neuropathologic changes in the brain. SETTING: Academic research. Patients The study included 123 patients (79 with clinically diagnosed AD, 29 with other dementia, and 15 with other neurologic disease). All underwent clinical evaluation and provided antemortem lumbar CSF samples, and neuropathologic data were collected from September 11, 1990, to March 13, 2003, in the Department of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland. MAIN OUTCOME MEASURES: Levels of CSF Abeta42, total tau, and phosphorylated tau protein were measured using standard commercial immunoassays. Neuropathologic evaluations included the classic silver impregnation method and immunohistochemistry for Abeta, hyperphosphorylated tau, and alpha-synuclein. RESULTS: Cerebrospinal fluid Abeta42 and tau protein levels were related to amyloid load and the presence of neurofibrillary pathologic abnormalities in the brain. Cerebrospinal fluid Abeta42 level correlated inversely with total Abeta load in the brain, and CSF tau level correlated with results of immunohistochemistry for hyperphosphorylated tau and with the presence of neocortical neurofibrillary tangles. In multivariate logistic regression analysis, the number of neuritic plaques in the brain remained a significant predictor of decreased CSF Abeta42 level and of increased CSF tau level. Based on the ratio of phosphorylated tau level to Abeta42 level, sensitivity was 91.6%, and specificity was 85.7%, with an overall accuracy of 90.2% for the presence of pathologic neuritic plaque in the brain. CONCLUSIONS: Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain. The combination of abnormally low CSF Abeta42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy. This combination assay may be helpful in diagnosing the presence of AD pathologic changes in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A characteristic biomarker profile, defined by reduced levels of Aβ42 in conjunction with elevated t-tau and p-tau, provides a robust biochemical signature for detecting AD pathology and distinguishing it from other neurodegenerative disorders72,73.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 895
P-tau217 as a Biomarker in Alzheimer’s Disease: Applications in Latin American Populations
Varela-Vidales, C. A., Martínez-Hernández, A., Hernández-Castellanos, E., & Delgado-Lara, D. L. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146633 · Cited by 9
Liu, F., Xu, L., Lin, Y., Deng, X., Dong, R., Wang, B., & Bi, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.978297 · Cited by 9
Li, M., Li, Y., Schindler, S. E., Yen, D. P., Sutcliffe, S., Babulal, G. M., Benzinger, T. L. S., Lenze, E. J., & Bateman, R. J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13125 · Cited by 9
Bonomi, C. G., Motta, C., Donna, M. G. D., Poli, M., Nuccetelli, M., Bernardini, S., Mercuri, N. B., Koch, G., & Martorana, A. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01617-2 · Cited by 11
Szalárdy, L., Zádori, D., Klivènyi, P., & Vécsei, L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160037 · Cited by 10
Lim, H. J., Park, J. E., Kim, B. C., Choi, S., Song, M., Cho, S. H., Seo, H. J., Kim, J., Song, H., Choi, K. Y., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191331 · Cited by 9
Chun, M. Y., Jang, H., Kim, H. J., Kim, J. P., Gallacher, J., Allué, J. A., Sarasa, L., Castillo, S., Pascual‐Lucas, M., Na, D. L., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1126799 · Cited by 9
Balasa, M., Dídac Vidal-piñeiro, A., Lladó, A., Antonell, A., Bosch, B., Castellanos, F., Bargalló, N., Bartrés‐Faz, D., Molinuevo, J. L., & Sánchez‐Valle, R. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111949 · Cited by 9
Cerebrospinal fluid in Creutzfeldt–Jakob disease
Zerr, I., Zafar, S., Schmitz, M., & Llorens, F. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00008-3 · Cited by 9
Haapalinna, F., Kokki, M., Jääskeläinen, O., Hallikainen, M., Helisalmi, S., Koivisto, A. M., Kokki, H. J., Paajanen, T. I., Penttinen, J., Pikkarainen, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170534 · Cited by 9
Self-citationAlzheimer’s Disease and Dementia
Lewis, P. A., & Spillane, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811069-0.00002-1 · Cited by 9
Kurihara, M., Kondo, S., Ohse, K., Nojima, H., Kikkawa-Saito, E., & Iwata, A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240185 · Cited by 8
Wang, Y.-H., Lin, W., Yang, L., Cai, S., Zhu, J., Feng, Y., Yang, L.-X., Feng, Z.-Z., Li, P., & Chen, J. (2016) · Asia Pacific Journal of Clinical Trials Nervous System Diseases · doi:10.4103/2468-5577.193144 · Cited by 8
Perspectives of the diagnosis of Alzheimer’s disease using optic coherent tomography
Bogolepova, A. N., Zhuravleva, A. N., & Makhnovich, E. V. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201711791112-117 · Cited by 8
Deep learning-based classification of multi-categorical Alzheimer's disease data.
Cohen, D. S., Carpenter, K. A., Jarrell, J. T., & Huang, X. (2019) · PubMed · Cited by 8
Ye, L., Gao, P.-R., Zhang, Y.-B., Cheng, H.-R., Tao, Q., Wu, Z., & Li, H. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s294756 · Cited by 8
Biomarkers and Their Implications in Alzheimer’s Disease: A Literature Review
Marcucci, V., & Kleiman, J. (2021) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2021.00016 · Cited by 8
Fei, Z., Pan, B., Pei, R., Chen, Z., Du, X., Cao, H., & Li, C. (2022) · Systematic Reviews · doi:10.1186/s13643-022-02115-y · Cited by 9
Gupta, S., Fiertag, O., & Warner, J. P. (2009) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.107.003558 · Cited by 11
Biomarkers for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00007-0 · Cited by 9
Ashford, M. T., Neuhaus, J. M., Jin, C., Camacho, M. R., Fockler, J., Truran, D., Mackin, R. S., Rabinovici, G. D., Weiner, M. W., & Nosheny, R. L. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12102 · Cited by 8
Use of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic
Stiffel, M., Bergeron, D., Amari, K. M., Poulin, É., Roberge, X., Meilleur‐Durand, S., Sellami, L., Molin, P., Nadeau, Y., Fortin, M., et al. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.67 · Cited by 9
Bias-generating factors in biofluid amyloid-β measurements for Alzheimer’s disease diagnosis
Park, S., & Kim, Y. S. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00201-z · Cited by 8
What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta, D., Initiative, A. D. N., Moullart, V., Schraen‐Maschke, S., Devendeville, A., Meyer, M.-É., & Godefroy, O. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150829 · Cited by 7
Singh, K., Cheung, B. M. Y., & Xu, A. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0219 · Cited by 7
Proteomic Markers and Early Prediction of Alzheimer’s Disease
Zakharova, N. V., Bugrova, A. E., Indeykina, M. I., Fedorova, Y. B., Колыхалов, И. В., Si, G., Николаев, Е. Н., & Kononikhin, A. S. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922080089 · Cited by 7
Predictors of Future Deep Brain Stimulation Surgery in de novo Parkinson's Disease
Lang, S., Vetkas, A., Conner, C. R., Kalia, L. V., Lozano, A. M., & Kalia, S. K. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13747 · Cited by 7
Cellular specificity is key to deciphering epigenetic changes underlying Alzheimer's disease
Signal, B., Suárez, T. G. P., Taberlay, P. C., & Woodhouse, A. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106284 · Cited by 8
Zhao, L., Zhang, M., Li, Q., Wang, X., Lu, J., Han, Y., & Cai, Y. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01983 · Cited by 8
The possible impact of cervical stenosis on cephalad neuronal dysfunction
Khachatryan, T., & Robinson, J. S. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.06.008 · Cited by 7
When Does Alzheimer’s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-Á., Cervera‐Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19305 · Cited by 7
Moreira, R., Mendonça, L. S., & de Almeida, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212288 · Cited by 7
Bruno, D., Grothe, M. J., Nierenberg, J. J., Teipel, S. J., Zetterberg, H., Blennow, K., & Pomara, N. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.002 · Cited by 7
Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects
Millard, S. P., Lutz, F., Li, G., Galasko, D. R., Farlow, M. R., Quinn, J. F., Kaye, J. A., Leverenz, J. B., Tsuang, D. W., Yu, C., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.07.027 · Cited by 8
Papel de los biomarcadores en el diagnóstico precoz de la enfermedad de Alzheimer
Molinuevo, J. L. (2011) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2011.10.008 · Cited by 7
Network-constrained technique to characterize pathology progression rate in Alzheimer’s disease
Powell, F., Tosun, D., Raj, A., & Initiative, A. D. N. (2021) · Brain Communications · doi:10.1093/braincomms/fcab144 · Cited by 7
Improvement of Learning and Memory by Morin, A Flavonoid in Young and Aged Mice
Dhingra, D., & Soni, K. (2016) · Pharmacologia · doi:10.5567/pharmacologia.2016.75.82 · Cited by 7
Manca, C., Jonveaux, T., Roch, V., Marie, P., Karcher, G., Lamiral, Z., Malaplate, C., & Verger, A. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09315-y · Cited by 7
Neuropathological substrates of cognition in Parkinson's disease
Coughlin, D. G., & Irwin, D. J. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.014 · Cited by 8
Integrative network analysis reveals novel moderators of Aβ-Tau interaction in Alzheimer's disease
Kitani, A., Matsui, Y., & Initiative, F. T. A. D. N. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01705-x · Cited by 6
The link between sleep duration and stroke risk
Cheng, Y., Ding, Y., Elmadhoun, A., Ji, X., & Cheng, Y. (2025) · Brain Circulation · doi:10.4103/bc.bc_7_24 · Cited by 6
Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer’s disease
Knudtzon, S. L., Nordengen, K., Grøntvedt, G. R., Jarholm, J. A., Eliassen, I. V., Selnes, P., Pålhaugen, L., Espenes, J., Gísladóttir, B., Waterloo, K. K., et al. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.05.016 · Cited by 6
Regulatory mechanism of circular RNAs in brain and neurodegenerative diseases
AmeliMojarad, M., & Amelimojarad, M. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1507575 · Cited by 6
Banerjee, S. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.115256 · Cited by 6
Gasparini‐Berenguer, R., Monge-Argilés, J. A., Ruiz, C. M., Payá, J. S., Cantó, M. A. B., & Santana, C. L. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000025 · Cited by 6
Vers une nouvelle définition de la maladie d’Alzheimer
Dubois, B. (2013) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31632-2 · Cited by 6
Albright, J., Ashford, M. T., Jin, C., Neuhaus, J. M., Rabinovici, G. D., Truran, D., Maruff, P. T., Mackin, R. S., Nosheny, R. L., & Weiner, M. W. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12207 · Cited by 6
Sacchi, L., Carandini, T., Fumagalli, G., Pietroboni, A. M., Contarino, V. E., Siggillino, S., Arcaro, M., Fenoglio, C., Zito, F., Marotta, G., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210593 · Cited by 6
Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway
Knapskog, A., Engedal, K., & Brækhus, A. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000126 · Cited by 6
Magnin, É., Dumurgier, J., Bouaziz-Amar, É., Bombois, S., Wallon, D., Gabelle, A., Lehmann, S., Blanc, F., Bousiges, O., Hannequin, D., et al. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.10.383 · Cited by 6
Amyloid Beta Adsorption Problem with Transfer Plates in Amyloid Beta 1–42 IVD Kits
Dursun, E., Alaylıoğlu, M., Bılgıç, B., Hanagasi, H. A., Gurvit, H. I., Emre, M., & Gezen‐Ak, D. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-1261-0 · Cited by 6
Malnar, M., Košiček, M., Béné, R., Tarnik, I. P., Pavelin, S., Božović, I. B., Brajenović‐Milić, B., Hečimović, H., Titlić, M., Demarin2, Z., et al. (2012) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2012-1899 · Cited by 6
The Relationship Between Suboptimal Social Networks and Postoperative Delirium: The PNDABLE Study
Tang, X., Yv, H., Fei, W., Wang, J., Liu, S., Wu, X., Dong, R., Lin, X., Wang, B., & Bi, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.851368 · Cited by 5
Saha, C., Figley, C. R., Dastgheib, Z. A., Lithgow, B., & Moussavi, Z. (2024) · Neuroscience Insights · doi:10.1177/26331055231225657 · Cited by 5
Translating NIA‐AA criteria into usual practice: Report from the ReDeMa Project
Sánchez‐Soblechero, A., Berbel, Á., Villarejo‐Galende, A., Palmí-Cortés, I., Vieira, A., Gil‐Moreno, M. J., Fernández, C., Martín-Montes, A., Carreras, M. T., Fernández, Y., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12451 · Cited by 5
Clinical Use of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease
Zetterberg, H., Lunn, M. P., & Herukka, S. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.47 · Cited by 5
Self-citationLinking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data
Guhra, M., Thomas, C., Boedeker, S., Kreisel, S. H., Drießen, M., Beblo, T., Ohrmann, P., & Toepper, M. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.11.008 · Cited by 5
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer’s Disease Trials of Bapineuzumab
Russu, A., Samtani, M. N., Xu, S. X., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S. V., Liu, E., Brashear, H. R., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151065 · Cited by 5
Semah, F., Deberdt, W. G., & Ceccaldi, M. P. (2016) · Médecine Nucléaire · doi:10.1016/j.mednuc.2016.08.001 · Cited by 5
The pitfalls of biomarker‐based classification schemes
Illán‐Gala, I., Vilaplana, E., Pegueroles, J., Montal, V., Alcolea, D. A., Blesa, R., Lleó, A., & Fortea, J. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.002 · Cited by 5
Association of PTHrP levels in CSF with Alzheimer’s disease biomarkers
Kushnir, M. M., Michno, W., Rockwood, A. L., Blennow, K., Strathmann, F. G., & Hanrieder, J. (2018) · Clinical mass spectrometry · doi:10.1016/j.clinms.2018.10.001 · Cited by 5
Aksnes, M., Müller, E. G., Tiiman, A., Edwin, T. H., Terenius, L. Y., Revheim, M.-E. R., Vukojević, V. B., Bogdanović, N., & Knapskog, A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200237 · Cited by 5
Development of a Low-Molecular-Weight Aβ42 Detection System Using a Enzyme-Linked Peptide Assay
Kim, S., Lee, E.-H., Kim, H., Kim, A.-R., Kim, Y.-E., Lee, J., Yoon, M., & Koh, S. (2021) · Biomolecules · doi:10.3390/biom11121818 · Cited by 5
A Novel Computational Proxy for Characterizing Cognitive Reserve in Alzheimer’s Disease
Zhang, Y., Initiative, A. D. N., Hao, Y., Li, L., Xia, K., & Guorong Wu, A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201011 · Cited by 6
Sha, S. J., & Rabinovici, G. D. (2016) · Wiley eBooks · doi:10.1002/9781118797662.ch3 · Cited by 5
Wang, W., Huang, R., Lv, L., Ma, X., Li, Z., Zhang, Y., Wu, J., Wu, S., Xu, J., Hu, Y., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2529565123 · Cited by 4
Integration over reduction: multimodal PET and fluid biomarkers in Alzheimer's disease and beyond
Blūma, M., Chiotis, K., & Nordberg, A. K. (2026) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001462 · Cited by 4
Andriuta, D., Moullart, V., Schraen‐Maschke, S., Devendeville, A., Meyer, M.-É., & Godefroy, O. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000225 · Cited by 4
Tau and Alzheimer’s Disease: Molecular Mechanisms and Treatment Approaches
Reiss, A. B., Muhieddine, D., Leon, A. Z. D., Voloshyna, I., Gomolin, I. H., & Pinkhasov, A. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-021-01092-y · Cited by 4
CSF Aβ40 Levels Do Not Correlate with the Clinical Manifestations of Alzheimer’s Disease
Castro, J. G., del Sol, H. M., Fraga, O. R., Hernández-Barral, M., Serrano-López, S., García, A. F., & Montes, Á. M. (2022) · Neurodegenerative Diseases · doi:10.1159/000530907 · Cited by 4
Personalized biocorona as disease biomarker: The challenges and opportunities
Talab, M. J., Valizadeh, A., Tahershamsi, Z., Housaindokht, M. R., & Ranjbar, B. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130724 · Cited by 4
Takahashi, H., Takami, Y., Takeda, S., Hayakawa, N., Nakajima, T., Takeya, Y., Matsuo, C., Arisawa, A., Rakugi, H., & Tomiyama, N. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8106 · Cited by 4
Cui, J., Zufferey, V., & Kherif, F. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000225 · Cited by 4
ZahediNasab, R., & Mohseni, H. (2018) · National and International Iranian Conference on Biomedical Engineering (ICBME) · doi:10.1109/icbme.2018.8703546 · Cited by 4
From model system to clinical medicine: pathophysiologic links of common proteinopathies
McMillan, P. J., & Leverenz, J. B. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt50 · Cited by 4
Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer’s Disease Biomarkers
Blanco-Cantó, M. E., Monge-Argilés, J. A., Pérez‐Cejuela, C., Badía, C., Gabaldón, L., Muñoz‐Ruiz, C., Sánchez–Payá, J., Gasparini‐Berenguer, R., & Leiva-Santana, C. (2017) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317516688298 · Cited by 5
Lombardi, G., Berti, V., Tedde, A., Bagnoli, S., Piaceri, I., Polito, C., Lucidi, G., Ferrari, C., Ginestroni, A., Moretti, M., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161170 · Cited by 4
Biomarkers and the diagnosis of preclinical dementia
Lilford, P., & Hughes, J. C. (2018) · BJPsych Advances · doi:10.1192/bja.2018.28 · Cited by 4
The Alzheimer’s Disease Metabolome: Effects of Sex and APOE ε4 genotypePreprint
Arnold, M., Nho, K. T., Kueider-Paisley, A., Massaro, T., Brauner, B., MahmoudianDehkordi, S., Louie, G., Moseley, M. A., Thompson, J. W., Williams, L. S. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/585455 · Cited by 4
Current status of fluid biomarkers for early Alzheimer's disease and FDA regulation implications
Jamerlan, A., An, S. S. A., & Hulme, J. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123325 · Cited by 3
Autophagy–exosome crosstalk in neurodegeneration: Mechanisms and therapeutic opportunities
Sedighi, S., Guan, T., Michetti, F., Cordani, M., Behrooz, A. B., Sabouni, F., Eshraghi, M., Saleem, A., Ghavami, S., & Aghanoori, M. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109025 · Cited by 3
ANU-ADRI scores, tau pathology, and cognition in non-demented adults: the CABLE study
Yin, S., Gao, P., Ou, Y., Fu, Y., Liu, Y., Wang, Z.-T., Han, B.-L., & Tan, L. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01427-6 · Cited by 5
Diagnosis and Treatment of Alzheimer’s Disease: Current Update
Yim, Y., & Moon, W. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2024.0146 · Cited by 3
Les marqueurs de la maladie d’Alzheimer prodromale
de Souza, L. C., Sarazin, M., Uspenskaya, O., Habert, M., Lamari, F., Lehéricy, S., & Dubois, B. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2012.07.005 · Cited by 6
Alzheimer's Disease Longitudinal Change in CSF Biomarkers in Autosomal-Dominant
Fagan, A. M. (2014) · Cited by 3
Cerebrospinal fluid analysis in individuals with diabetes-related dementia
Kanetaka, H., Fukasawa, R., Shimizu, S., Takenoshita, N., & Hanyu, H. (2017) · eNeurologicalSci · doi:10.1016/j.ensci.2017.06.002 · Cited by 3
Zenuni, H., Candelise, N., Grillo, P., Simonetta, C., Bovenzi, R., Ferri, A., Valle, C., Mercuri, N. B., & Schirinzi, T. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2106165 · Cited by 3
Low synaptic and neurosecretory proteins in cerebrospinal fluid in early parkinsonian disease
Jakobsson, P., Nilsson, J., Nygren, M., Zetterberg, H., Blennow, K., Constantinescu, R., Constantinescu, J., Brinkmalm, A., & Bäckström, D. C. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123683 · Cited by 3
Tang, P.-U., Wu, I.-H., Lao, I.-H., Leong, W., & Hu, C. (2020) · Innovations in Digital Health Diagnostics and Biomarkers · doi:10.36401/iddb-20-04 · Cited by 3
Lorenzini, L., Ingala, S., Wottschel, V., Wink, A. M., Mutsaerts, H. J. M. M., Haller, S., Blennow, K., O'Brien, J. T., Frisoni, B. G., Chételat, G., et al. (2022) · Aging Brain · doi:10.1016/j.nbas.2022.100054 · Cited by 3
Grey Matter and Cognitive Patterns in Cognitive Impaired Subjects Using CSF Biomarker Cut-Offs
Miralbell, J., Spulber, G., Hooshmand, B., Besga, A., Mataró, M., Cedazo-Mı́nguez, Á., Kivipelto, M., & Wahlund, L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111553 · Cited by 3
Risk Factors for Post-Lumbar Puncture Headache in a Study of Alzheimer's Disease Biomarkers
Park, Y. H., Wang, M. J., Jang, J., Park, Y. H., Lee, J. W., & Kim, S. (2015) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2015.14.1.12 · Cited by 3
Leskelä, S., Takalo, M., Marttinen, M., Huber, N., Paananen, J., Mitra, V., Rauramaa, T. H., Mäkinen, P. M., Leinonen, V., Soininen, H. S., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170362 · Cited by 3
Self-citationBiomarkers of Disorders of the Nervous System
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7431-3_14 · Cited by 3
NMR metabolomics techniques and mathematical tools as an aid in neurological diagnosis
Jukarainen, N. (2009) · UEF eRepo (University of Eastern Finland) · Cited by 3
Where Should I Draw the Line: PET-Driven, Data-Driven, or Manufacturer Cut-Off?
Sánchez‐Soblechero, A., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Irure, J., López‐Hoyos, M., Jiménez-Bonilla, J. F., Quirce, R., de Arcocha-Torres, M., Cuenca-Vera, O., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230678 · Cited by 2
Fluid Markers of Alzheimer Disease
Sutphen, C. L., Volluz, K., & Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_8 · Cited by 2
Systematic review of health economic models for assessment and diagnosis of dementia
Kwon, J., Schoutens, L., Burden, M., Colam, C., Zhao, S., Maldonado, B. N., Blundell, E., Krywonos, A., Jiang, J., Karagiannidou, M., et al. (2025) · Alzheimer s & Dementia Behavior & Socioeconomics of Aging · doi:10.1002/bsa3.70027 · Cited by 2
Giacomucci, G., Tabbì, S. M. R., Ingannato, A., Bagnoli, S., Padiglioni, S., Crucitti, C., Sensi, C., Sanesi, S., Moschini, V., Morinelli, C., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70285 · Cited by 2
Bernocchi, F., Bonomi, C. G., Poli, M., Donna, M. G. D., Terrinoni, A., Motta, C., & Martorana, A. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08973-x · Cited by 2
Metadata
- Authors
- Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T.
- Affiliations
- University of Eastern Finland (FI)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-01
- Volume
- 66
- Issue
- 3
- Pages
- 382-9
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2075193321
- Cited by
- 896
- References
- 29
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 45 · 2023: 27 · 2022: 34 · 2021: 78 · 2020: 89 · 2019: 75 · 2018: 60 · 2017: 59 · 2016: 51 · 2015: 65 · 2014: 48 · 2013: 63 · 2012: 41
- FWCI
- 32.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kuopion Yliopistollinen Sairaala
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, tau protein, phosphorylated tau, amyloid plaques, neurofibrillary tangles, diagnostic accuracy, lumbar CSF, neurodegeneration, alpha-synuclein, postmortem neuropathology, biomarker ratios, sensitivity and specificity
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cross-Sectional Studies, Dementia, Female, Humans, Immunoassay, Male, Nervous System Diseases, Peptide Fragments, Retrospective Studies, ROC Curve, Logistic Models, Amyloid beta-Peptides, Silver Staining, tau Proteins, Statistics, Nonparametric, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
